Debanjana Chatterjee

Debanjana Chatterjee, PhD, is a seasoned professional in health economics and outcomes research, currently serving as Director of Global HEOR Cell Therapy for Autoimmune at Bristol Myers Squibb since August 2021. Chatterjee leads the development of value demonstration strategies and patient-reported outcomes for novel therapies in autoimmune diseases, focusing on the CAR-T pipeline. Prior roles at Bristol Myers Squibb included directing real-world evidence generation for hematology products and overseeing health equity initiatives in population health marketing. Previous experience encompasses senior positions at Boehringer Ingelheim and Eisai, where Chatterjee concentrated on health economics and real-world evidence generation in oncology and neurology. Academic credentials include a PhD in Population Health Sciences and multiple advanced degrees from the University of Wisconsin-Madison and Jadavpur University.